About Viewray (NASDAQ:VRAY)
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.
Industry, Sector and Symbol
Industry Advanced Medical Equipment & Technology
Trailing P/E Ratio-7.35398230088496
Forward P/E Ratio-7.91
Sales & Book Value
Annual Sales$22.24 million
Price / Sales25.24
Price / CashN/A
Book Value($1.00) per share
Price / Book-8.31
Return on EquityN/A
Return on Assets-59.34%
Viewray (NASDAQ:VRAY) Frequently Asked Questions
What is Viewray's stock symbol?
Viewray trades on the NASDAQ under the ticker symbol "VRAY."
How were Viewray's earnings last quarter?
Viewray Inc (NASDAQ:VRAY) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.07. The company had revenue of $12.20 million for the quarter, compared to analysts' expectations of $18.63 million. The business's revenue was up 2950.0% on a year-over-year basis. View Viewray's Earnings History.
Where is Viewray's stock going? Where will Viewray's stock price be in 2018?
6 equities research analysts have issued 12 month price objectives for Viewray's shares. Their predictions range from $10.00 to $13.50. On average, they anticipate Viewray's stock price to reach $11.58 in the next twelve months. View Analyst Ratings for Viewray.
What are Wall Street analysts saying about Viewray stock?
Here are some recent quotes from research analysts about Viewray stock:
- 1. Mizuho analysts commented, "We are not too concerned because the of usual lumpiness at the beginning of new operations. Management remains confident it can complete installation of 7-8 units before year-end. On the positive side, new orders received grew to $29.9 mil vs. our est. of $24.3 mil. Given the favorable development in Europe, Q4 back orders may exceed our expectations." (11/13/2017)
- 2. Northland Securities analysts commented, "We are maintaining our FY17 & FY18 numbers, and our PT & ratings remain the same. Key Points Perhaps the most interesting takeaway from the call was the announcement of a multi-institutional trial on unresectable pancreatic cancer using MRIdian. It is our understanding that this trial will include both MRIdian Cobalt & LINAC (as they become available); will include a hard endpoint like survival, and possibly" intraop dose titration and impact on outcomes. As a reminder, most patients with pancreatic cancer will die within 1 – 2 years, with median survival @ 1-year. Hence, it is certainly possible that ViewRay could provide survival endpoints for such a trial in late 2018 / early 2019. This obviously is predicated on the trial design, sample size, inclusion criteria, and whether this will be randomized or not. The ideal design would obviously be to include a comparative arm with another RT machine (like the TruBeam) & compare to MRIdian. Finally, how outcomes will be influenced with the use of Cobalt vs. LINAC will also be interesting to note, although it might be hard to draw any statistical conclusions given small sample size." (5/16/2017)
- 3. Aegis analysts commented, "We are assuming coverage of VRAY with a Buy rating and $11 PT. We believe the MRI-guided LINAC is a game-changer in radiation oncology, with real-time imaging improving dosimetry and reducing the toxicity to patients. The combination improves functionality and expands the use of stereotactic body radiation therapy (SBRT), and physicians believe the system can expand the total treatable tumors by at least 20%." (5/16/2017)
Who are some of Viewray's key competitors?
Some companies that are related to Viewray include Natus Medical (BABY), Volcano (VOLC), Luminex (LMNX), LeMaitre Vascular (LMAT), Accuray (ARAY), Pacific Biosciences of California (PACB), Pulse Biosciences (PLSE), GenMark Diagnostics (GNMK), Cytosorbents (CTSO), Cogentix Medical (CGNT), Corindus Vascular Robotics (CVRS), Harvard Bioscience (HBIO), Alliance HealthCare Services (AIQ), Viveve Medical (VIVE), Fulgent Genetics (FLGT), IRIDEX (IRIX), Edap Tms (EDAP) and Luna Innovations (LUNA).
When did Viewray IPO?
(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.
Who owns Viewray stock?
Viewray's stock is owned by many different of institutional and retail investors. Top institutional investors include Park West Asset Management LLC (3.87%), BlackRock Inc. (2.74%), RTW Investments LP (2.00%), Sectoral Asset Management Inc (1.40%), Citadel Advisors LLC (0.99%) and Next Century Growth Investors LLC (0.88%). Company insiders that own Viewray stock include Aditya Puri, Ajay Bansal, David P Bonita, Fmr Llc and Henry A Mckinnell. View Institutional Ownership Trends for Viewray.
Who sold Viewray stock? Who is selling Viewray stock?
Viewray's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Falcon Point Capital LLC, TIAA CREF Investment Management LLC, Raymond James & Associates and Next Century Growth Investors LLC. View Insider Buying and Selling for Viewray.
Who bought Viewray stock? Who is buying Viewray stock?
Viewray's stock was bought by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Sectoral Asset Management Inc, Citadel Advisors LLC, EAM Investors LLC, RTW Investments LP, BlackRock Inc., Bank of New York Mellon Corp and Perceptive Advisors LLC. Company insiders that have bought Viewray stock in the last two years include Aditya Puri, Ajay Bansal, David P Bonita and Henry A Mckinnell. View Insider Buying and Selling for Viewray.
How do I buy Viewray stock?
Shares of Viewray can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viewray's stock price today?
One share of Viewray stock can currently be purchased for approximately $8.31.
How big of a company is Viewray?
Viewray has a market capitalization of $565.34 million and generates $22.24 million in revenue each year. The company earns $-50,630,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Viewray employs 92 workers across the globe.
How can I contact Viewray?
Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 14407033210 or via email at [email protected]
MarketBeat Community Rating for Viewray (VRAY)MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Viewray (NASDAQ:VRAY) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$11.58||$11.20||$10.60||$9.50|
|Price Target Upside: ||41.61% upside||24.58% upside||12.41% upside||83.75% upside|
Viewray (NASDAQ:VRAY) Consensus Price Target History
Viewray (NASDAQ:VRAY) Analyst Ratings History
(Data available from 2/23/2016 forward)
Viewray (NASDAQ:VRAY) Earnings History and Estimates Chart
Viewray (NASDAQ VRAY) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/13/2017||Q3 2017||($0.12)||($0.19)||$18.63 million||$12.20 million||View||N/A|
|8/7/2017||Q2 2017||($0.24)||($0.26)||$0.68 million||$0.70 million||View||Listen|
|5/15/2017||Q1 2017||($0.22)||($0.24)||$0.52 million||$1.23 million||View||N/A|
|3/16/2017||Q4 2016||($0.34)||($0.25)||$13.65 million||$16.13 million||View||N/A|
|11/14/2016||Q316||($0.27)||($0.35)||$0.39 million||$0.36 million||View||N/A|
|8/15/2016||Q216||($0.29)||($0.32)||$5.53 million||$0.30 million||View||Listen|
|5/13/2016||Q116||($0.30)||($0.35)||$5.50 million||$5.50 million||View||N/A|
|3/28/2016||Q4 2015||($0.37)||$4.61 million||View||N/A|
|11/9/2015||Q3 2015||($0.35)||$5.32 million||View||N/A|
Viewray (NASDAQ:VRAY) Earnings Estimates
2018 EPS Consensus Estimate: ($0.81)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Viewray (NASDAQ:VRAY)
No dividend announcements for this company have been tracked by MarketBeat.com
Viewray (NASDAQ VRAY) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 62.81%
Institutional Ownership Percentage: 51.24%
Viewray (NASDAQ VRAY) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|4/25/2017||Fmr Llc||Insider||Sell||106,781||$6.76||$721,839.56|| |
|4/24/2017||Fmr Llc||Insider||Sell||101,139||$6.71||$678,642.69|| |
|4/20/2017||Fmr Llc||Insider||Sell||101,236||$6.90||$698,528.40|| |
|4/18/2017||Fmr Llc||Insider||Sell||107,217||$7.24||$776,251.08|| |
|4/13/2017||Fmr Llc||Insider||Sell||115,860||$7.44||$861,998.40|| |
|4/12/2017||Fmr Llc||Insider||Sell||179,494||$7.40||$1,328,255.60|| |
|4/10/2017||Fmr Llc||Insider||Sell||178,556||$7.77||$1,387,380.12|| |
|4/7/2017||Fmr Llc||Insider||Sell||52,050||$7.89||$410,674.50|| |
|4/5/2017||Fmr Llc||Insider||Sell||196,397||$7.90||$1,551,536.30|| |
|4/3/2017||Fmr Llc||Insider||Sell||217,883||$8.29||$1,806,250.07|| |
|3/30/2017||Fmr Llc||Insider||Sell||28,661||$8.46||$242,472.06|| |
|1/18/2017||Ajay Bansal||CFO||Buy||62,597||$3.17||$198,432.49||70,104|| |
|1/18/2017||Henry A. Mckinnell||Director||Buy||312,989||$3.17||$992,175.13|| |
|9/9/2016||Aditya Puri||Director||Buy||1,472,803||$2.95||$4,344,768.85||18,964|| |
|8/22/2016||David P Bonita||Director||Buy||1,138,074||$2.95||$3,357,318.30|| |
Viewray (NASDAQ VRAY) News Headlines
|Viewray (VRAY) vs. Waters (WAT) Critical Contrast|
www.americanbankingnews.com - February 19 at 3:16 PM
|BIOLASE (BIOL) and Viewray (VRAY) Head to Head Contrast|
www.americanbankingnews.com - February 18 at 1:44 PM
|Viewray (VRAY) Stock Rating Lowered by BidaskClub|
www.americanbankingnews.com - February 18 at 1:00 PM
|$20.09 Million in Sales Expected for Viewray Inc (VRAY) This Quarter|
www.americanbankingnews.com - February 16 at 5:34 AM
|Viewray Inc (VRAY) to Post FY2017 Earnings of ($1.08) Per Share, B. Riley Forecasts|
www.americanbankingnews.com - February 12 at 1:08 AM
|Viewray (VRAY) Now Covered by Analysts at B. Riley|
www.americanbankingnews.com - February 11 at 3:24 PM
|Viewray Inc (VRAY) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - February 10 at 7:50 AM
|ViewRay Appoints Scott Huennekens and Daniel Moore to its Board of Directors|
finance.yahoo.com - February 8 at 7:22 AM
|FY2017 Earnings Estimate for Viewray Inc (VRAY) Issued By Cantor Fitzgerald|
www.americanbankingnews.com - January 31 at 8:32 AM
|Viewray Inc (VRAY) Expected to Announce Quarterly Sales of $20.42 Million|
www.americanbankingnews.com - January 30 at 6:16 AM
|Zacks: Brokerages Anticipate Viewray Inc (VRAY) to Announce -$0.29 Earnings Per Share|
www.americanbankingnews.com - January 28 at 11:16 AM
|Morning Technical Insight on These Medical Equipment Stocks -- ReWalk Robotics, Avinger, ViewRay, and Align Technology|
www.bizjournals.com - January 26 at 7:29 AM
|Viewray (VRAY) versus GenMark Diagnostics (GNMK) Head-To-Head Survey|
www.americanbankingnews.com - January 21 at 5:26 AM
|FY2017 EPS Estimates for Viewray Inc (VRAY) Decreased by Analyst|
www.americanbankingnews.com - January 19 at 10:08 AM
|Viewray Inc to Post FY2019 Earnings of $0.31 Per Share, Zacks Investment Research Forecasts (VRAY)|
www.americanbankingnews.com - January 18 at 9:04 PM
|Viewray (VRAY) vs. Pacific Biosciences of California (PACB) Head to Head Review|
www.americanbankingnews.com - January 18 at 3:30 PM
|Head to Head Survey: Viewray (VRAY) & Pacific Biosciences of California (PACB)|
www.americanbankingnews.com - January 17 at 3:12 AM
|VRAY: 2017 Financial Highlights. What To Expect In 2018|
finance.yahoo.com - January 16 at 4:20 PM
|Viewray Inc (VRAY) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - January 16 at 8:32 AM
|Viewray Sees Unusually High Options Volume (VRAY)|
www.americanbankingnews.com - January 12 at 1:28 AM
| Analysts Expect Viewray Inc (VRAY) Will Post Earnings of -$0.15 Per Share|
www.americanbankingnews.com - January 11 at 11:41 AM
|Brokers Offer Predictions for Viewray Inc's FY2017 Earnings (VRAY)|
www.americanbankingnews.com - January 10 at 6:30 AM
|ViewRay (VRAY) Reports Prelim 4Q & FY17 Revenues Above Consensus|
www.streetinsider.com - January 8 at 4:27 PM
|ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results|
finance.yahoo.com - January 8 at 10:47 AM
|Investors Buy High Volume of Viewray Call Options (VRAY)|
www.americanbankingnews.com - January 7 at 2:40 AM
|Viewray (VRAY) Rating Reiterated by Cantor Fitzgerald|
www.americanbankingnews.com - January 6 at 11:10 PM
|Pre-Open Movers 01/05: (CNIT) (DWCH) (FC) Higher; (OHRP) (RGNX) (FRAN) Lower (more...)|
www.streetinsider.com - January 5 at 10:48 AM
|-$0.15 EPS Expected for Viewray Inc (VRAY) This Quarter|
www.americanbankingnews.com - December 26 at 1:08 AM
|Viewray (VRAY) Stock Rating Upgraded by BidaskClub|
www.americanbankingnews.com - December 22 at 1:02 PM
|Viewray Inc (VRAY) Given Average Rating of "Buy" by Analysts|
www.americanbankingnews.com - December 22 at 8:58 AM
|Oncology Experts to Convene for Symposium to Advance MR Image-Guided Radiation Therapy|
finance.yahoo.com - December 19 at 10:39 AM
|ViewRay Inc (NASDAQ:VRAY): Does 20.2% EPS Decline Lately Make It An Underperformer?|
finance.yahoo.com - December 15 at 11:03 AM
|ETFs with exposure to ViewRay, Inc. : December 11, 2017|
finance.yahoo.com - December 11 at 4:29 PM
|$29.68 Million in Sales Expected for Viewray Inc (VRAY) This Quarter|
www.americanbankingnews.com - December 10 at 9:54 AM
|ViewRay (VRAY) Downgraded by BidaskClub to Hold|
www.americanbankingnews.com - December 9 at 6:22 AM
|Zacks: Analysts Anticipate ViewRay, Inc. (VRAY) Will Announce Earnings of -$0.15 Per Share|
www.americanbankingnews.com - December 8 at 8:06 AM
|ViewRay (VRAY) Lowered to "Sell" at ValuEngine|
www.americanbankingnews.com - December 2 at 12:40 AM
|ETFs with exposure to ViewRay, Inc. : November 30, 2017|
finance.yahoo.com - November 30 at 4:20 PM
|ViewRay, Inc. :VRAY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017|
finance.yahoo.com - November 29 at 10:43 AM
|ViewRay, Inc. (VRAY) Receives Consensus Rating of "Buy" from Analysts|
www.americanbankingnews.com - November 27 at 7:46 AM
|Financial Review: ViewRay (VRAY) vs. Presbia PLC (LENS)|
www.americanbankingnews.com - November 22 at 7:14 PM
|ViewRay® to Participate in Upcoming Conferences|
finance.yahoo.com - November 22 at 5:28 PM
|ViewRay, Inc. (VRAY) Expected to Announce Quarterly Sales of $29.68 Million|
www.americanbankingnews.com - November 22 at 8:17 AM
|ViewRay, Inc. to Post FY2017 Earnings of ($0.88) Per Share, Zacks Investment Research Forecasts (VRAY)|
www.americanbankingnews.com - November 22 at 5:52 AM
|VRAY: Financial Results For Third Quarter 2017. Revising Revenue Guidance|
finance.yahoo.com - November 20 at 3:59 PM
|ViewRay, Inc. (VRAY) Expected to Announce Earnings of -$0.10 Per Share|
www.americanbankingnews.com - November 20 at 11:46 AM
|ViewRay's (VRAY) "Buy" Rating Reaffirmed at Northland Securities|
www.americanbankingnews.com - November 18 at 5:36 PM
|Why ViewRay, Inc. Jumped Today|
finance.yahoo.com - November 18 at 10:08 AM
|Comparing Thermo Fisher Scientific (TMO) and ViewRay (VRAY)|
www.americanbankingnews.com - November 14 at 3:39 PM
|Edited Transcript of VRAY earnings conference call or presentation 13-Nov-17 1:30pm GMT|
finance.yahoo.com - November 13 at 9:44 PM
Viewray (NASDAQ:VRAY) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Viewray (NASDAQ VRAY) Stock Chart for Friday, February, 23, 2018